0001730430
false
0001730430
2023-07-25
2023-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 25, 2023
Kiniksa Pharmaceuticals, Ltd.
(Exact name of Registrant as Specified in Its
Charter)
Bermuda |
|
001-730430 |
|
98-1327726 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM11, Bermuda
(808) 451-3453
(Address, zip code and telephone number,
including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(781) 431-9100
(Address, zip code and telephone number,
including area code of agent for service)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
Class A
Common Shares $0.000273235 par value |
|
KNSA |
|
The Nasdaq Stock Market LLC |
|
|
|
|
(Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On July 25, 2023, Kiniksa Pharmaceuticals, Ltd.
issued a press release announcing financial results for the quarter ended June 30, 2023. A copy of the press release is furnished
with this Current Report on Form 8-K as Exhibit 99.1.
The information contained in this Item 2.02 of this
Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of
any general incorporation language in such filing and except as expressly provided by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
KINIKSA PHARMACEUTICALS, LTD. |
Date: July 25,
2023 |
By: |
/s/ Madelyn Zeylikman |
|
|
Madelyn Zeylikman |
|
|
Senior Vice President, General Counsel
and Secretary |
Exhibit 99.1
Kiniksa Pharmaceuticals
Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST®
(rilonacept) Q2 2023 net product revenue of $54.5 million –
– ARCALYST
2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint –
– KPL-404
Phase 2 rheumatoid arthritis data expected in 1H 2024 –
– Cash
reserves now expected to fund operations into at least 2027 –
– Conference
call and webcast scheduled for 8:30 am ET today –
HAMILTON, BERMUDA
– July 25, 2023 – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company
with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second
quarter 2023 financial results and recent portfolio execution.
“Kiniksa continues to make significant progress in bringing ARCALYST,
the first and only FDA-approved therapy for recurrent pericarditis, to patients in need. As a result of increased call frequency and expanded
reach with target prescribers, we are seeing increased prescriber adoption and patient enrollments. We are still in the early stages of
building the recurrent pericarditis market and remain encouraged by the high level of patient satisfaction, payer approval rates, and
duration of therapy. These key metrics provide conviction in raising our 2023 ARCALYST sales guidance to between $220 million and $230
million,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Within our pipeline, we continue to enroll
patients in the KPL-404 Phase 2 trial in rheumatoid arthritis and expect data in the first half of 2024. Additionally, we have a strong
financial position and our cash reserves, combined with our continued ARCALYST commercial execution and financial discipline, now provide
cash runway into at least 2027.”
Portfolio and Collaboration Execution
ARCALYST (IL-1α and IL-1β cytokine trap)
| • | ARCALYST net product revenue was $54.5 million for the second quarter of
2023. |
| • | Since launch, more than 1,250 prescribers have written ARCALYST prescriptions
for recurrent pericarditis. |
| • | As of the end of the second quarter of 2023, average total duration of ARCALYST
therapy in recurrent pericarditis was approximately 20 months. |
| - | Average total duration of therapy includes the approximately 45% of patients
who restarted ARCALYST, within an average of 8 weeks, after having discontinued therapy. |
KPL-404 (monoclonal antibody inhibitor of CD40-CD154 interaction)
| • | Kiniksa is enrolling patients in the Phase 2 clinical trial of KPL-404 in
rheumatoid arthritis. The company expects data from the trial in the first half of 2024. |
Mavrilimumab (monoclonal antibody inhibitor targeting GM-CSFRα)
| • | Kiniksa is pursuing collaborative study agreements to evaluate the potential
of mavrilimumab in rare cardiovascular diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been
implicated. |
Vixarelimab (monoclonal antibody inhibitor of signaling through
OSMRβ)
| • | In the second quarter of 2023, Kiniksa recognized a $15.0 million development
milestone related to a new indication under its global license agreement with Genentech, a member of the Roche Group (Genentech). |
Financial Results
| • | Total revenue for the second quarter of 2023 was $71.5 million, compared
to $27.0 million for the second quarter of 2022. |
| - | Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST
net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue
and $0.0 million in license and collaboration revenue for the second quarter of 2022. |
| • | Total operating expenses for the second quarter of 2023 were $74.6 million,
compared to $46.3 million for the second quarter of 2022. |
| - | Total operating expenses for the second quarter of 2023 included $6.5 million
in non-cash, share-based compensation expense, compared to $6.7 million for the second quarter of 2022. |
| • | Net income for the second quarter of 2023 was $15.0 million, compared to
a net loss of $20.0 million for the second quarter of 2022. |
| - | Net income for the second quarter of 2023 included a $16.2 million tax benefit
primarily due to the release of a valuation allowance on non-cash deferred tax assets. |
| • | As of June 30, 2023, Kiniksa had $185.0 million of cash, cash equivalents,
and short-term investments and no debt. |
Financial Guidance
| • | Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million
and $230 million compared to prior guidance of between $200 million and $215 million. |
| • | Kiniksa now expects that its cash and cash equivalents will fund its current
operating plan into at least 2027. |
Conference Call Information
| • | Kiniksa will host a conference call and webcast
at 8:30 a.m. Eastern Time on Tuesday, July 25, 2023, to discuss second quarter 2023 financial results and recent portfolio execution. |
| • | Individuals
interested in participating in the call via telephone may register here. Upon registration,
all telephone participants will receive a confirmation email detailing how to join the conference
call, including the dial-in number along with a unique passcode and registrant ID that can
be used to access the call. To access the webcast, please visit the Investors and Media section
of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s
website within approximately 48 hours after the event. |
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring,
developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical
need. Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated
mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For
more information, please visit www.kiniksa.com.
About ARCALYST
ARCALYST is a weekly, subcutaneously
injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling.
ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration
(FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and
Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST
for the treatment of recurrent pericarditis in 2019 and Orphan Drug designation to ARCALYST for the treatment of pericarditis in 2020.
The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.
IMPORTANT SAFETY INFORMATION
ABOUT ARCALYST
| • | ARCALYST may affect your immune system and can lower
the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened
in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped
if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming
back (chronic infection). |
| • | While taking ARCALYST, do not take other medicines
that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel®
(etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting
a serious infection. |
| • | Talk with your doctor about your vaccine history.
Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. |
| • | Medicines that affect the immune system may increase
the risk of getting cancer. |
| • | Stop taking ARCALYST and call your doctor or get
emergency care right away if you have any symptoms of an allergic reaction. |
| • | Your doctor will do blood tests to check for changes
in your blood cholesterol and triglycerides. |
| • | Common side effects include injection-site reactions
(which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection
site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. |
For more information
about ARCALYST, talk to your doctor and see the Product Information.
About KPL-404
KPL-404 is an investigational
humanized monoclonal antibody that is designed to inhibit CD40-CD154 (CD40 ligand) interaction, a key T-cell co-stimulatory signal critical
for B-cell maturation and immunoglobulin class switching and Type 1 immune responses. Kiniksa believes disrupting the CD40-CD154 interaction
is an attractive approach to address multiple autoimmune disease pathologies.
About Mavrilimumab
Mavrilimumab is an investigational
fully human monoclonal antibody that blocks activity of GM-CSF by specifically binding to the alpha subunit of the GM-CSF receptor (GM-CSFRα).
Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints
with statistical significance. Kiniksa is evaluating the development of mavrilimumab in rare cardiovascular diseases where the GM-CSF
mechanism has been implicated.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking
statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST
full-year 2023 net product revenue will be between $220 million and $230 million; our expectation that we will report data from our Phase
2 clinical trial of KPL-404 in rheumatoid arthritis in the first half of 2024; our expectation about our cash reserves funding our current
operating plan into at least 2027; our beliefs about the mechanisms of action of our product candidates and potential impact of their
approach, including that using KPL-404 to disrupt the CD40-CD154 interaction is an attractive approach to address multiple autoimmune
disease pathologies; and our belief that all of our product candidates offer the potential for differentiation.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty
in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our
clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data
from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us
or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential
undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction
of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval
of any of our product candidates or require additional data or trials to support approval; inability to successfully execute on our commercial
strategy for ARCALYST; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products
and product candidates; our reliance on Regeneron as the current sole manufacturer of ARCALYST; risks arising from our ongoing technology
transfer of ARCALYST drug substance manufacturing; raw material, important ancillary product and drug substance and/or drug product shortages;
our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications
in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; changes
in our operating plan, business development strategy or funding requirements; and existing or new competition.
These and other important factors discussed in our filings with the
U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual
results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention
or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing
our views as of any date subsequent to the date of this press release.
ARCALYST® is a registered trademark of Regeneron. All
other trademarks are the property of their respective owners.
Every Second Counts! ®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
KINIKSA PHARMACEUTICALS, LTD.
SELECTED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue: | |
| | |
| | |
| | |
| |
Product revenue, net | |
$ | 54,495 | | |
$ | 26,972 | | |
$ | 97,154 | | |
$ | 49,161 | |
License and collaboration revenue | |
| 16,978 | | |
| — | | |
| 22,664 | | |
| 10,000 | |
Total revenue | |
| 71,473 | | |
| 26,972 | | |
| 119,818 | | |
| 59,161 | |
Costs and operating expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of goods sold | |
| 7,699 | | |
| 5,029 | | |
| 14,735 | | |
| 9,248 | |
Collaboration expenses | |
| 13,986 | | |
| 3,672 | | |
| 22,274 | | |
| 11,926 | |
Research and development | |
| 23,767 | | |
| 13,798 | | |
| 38,939 | | |
| 34,615 | |
Selling, general and administrative | |
| 29,175 | | |
| 23,841 | | |
| 58,220 | | |
| 46,059 | |
Total operating expenses | |
| 74,627 | | |
| 46,340 | | |
| 134,168 | | |
| 101,848 | |
Loss from operations | |
| (3,154 | ) | |
| (19,368 | ) | |
| (14,350 | ) | |
| (42,687 | ) |
Other income | |
| 1,915 | | |
| 103 | | |
| 3,747 | | |
| 137 | |
Loss before income taxes | |
| (1,239 | ) | |
| (19,265 | ) | |
| (10,603 | ) | |
| (42,550 | ) |
Benefit (provision) for income taxes | |
| 16,211 | | |
| (716 | ) | |
| 13,305 | | |
| (2,641 | ) |
Net income (loss) | |
$ | 14,972 | | |
$ | (19,981 | ) | |
$ | 2,702 | | |
$ | (45,191 | ) |
Net income (loss) per share attributable to common shareholders—basic | |
$ | 0.21 | | |
$ | (0.29 | ) | |
$ | 0.04 | | |
$ | (0.65 | ) |
Net income (loss) per share attributable to common shareholders—diluted | |
$ | 0.21 | | |
$ | (0.29 | ) | |
$ | 0.04 | | |
$ | (0.65 | ) |
Weighted average common shares outstanding—basic | |
| 69,918,287 | | |
| 69,289,972 | | |
| 69,835,452 | | |
| 69,213,860 | |
Weighted average common shares outstanding—diluted | |
| 71,634,729 | | |
| 69,289,972 | | |
| 71,420,026 | | |
| 69,213,860 | |
KINIKSA PHARMACEUTICALS, LTD.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
(Unaudited)
| |
As of | |
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Cash, cash equivalents, and short-term investments | |
$ | 184,992 | | |
$ | 190,608 | |
Working capital | |
| 198,568 | | |
| 195,994 | |
Total assets | |
| 484,332 | | |
| 459,672 | |
Accumulated deficit | |
| (489,332 | ) | |
| (492,034 | ) |
Total shareholders' equity | |
| 411,656 | | |
| 396,149 | |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
過去 株価チャート
から 8 2024 まで 9 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
過去 株価チャート
から 9 2023 まで 9 2024